Skip to Main Content

Paper Details

pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry.
Br J Cancer
26
2018
ATM, ATM-deficient models, ATR, AZD0156, AZD6738, Ser635, TNBC, TNBC patient, ataxia-telangiectasia, ataxia-telangiectasia-kinase, ataxia-telangiectasia-mutated and Rad3-related, cancer, colorectal cancer, colorectal cancers, gastric cancers, glioblastoma-multiformes, irinotecan, olaparib, pRAD50, patient, patients, triple-negative-breast cancers
Author NameAffiliation
Jeffrey R WhiteakerClinical Research Division, Fred Hutchinson Cancer Research Centre
Lei ZhaoClinical Research Division, Fred Hutchinson Cancer Research Centre
William J Howat
William J Howat
J. Carl Barrett
Amanda G PaulovichClinical Research Division, Fred Hutchinson Cancer Research Centre
  • 1 - 6

Datasets

Release 1.2